RI-002
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Immune Deficiency Disorder
Conditions
Primary Immune Deficiency Disorder
Trial Timeline
Feb 1, 2014 → Jan 1, 2015
NCT ID
NCT01814800About RI-002
RI-002 is a phase 3 stage product being developed by ADMA Biologics for Primary Immune Deficiency Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT01814800. Target conditions include Primary Immune Deficiency Disorder.
What happened to similar drugs?
20 of 20 similar drugs in Primary Immune Deficiency Disorder were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01814800 | Phase 3 | Completed |
Competing Products
20 competing products in Primary Immune Deficiency Disorder